ImmunityBio (NASDAQ:IBRX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a report released on Friday,Benzinga reports. The brokerage currently has a $30.00 price target on the stock.

Separately, EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd.

ImmunityBio Stock Down 1.9 %

ImmunityBio stock opened at $2.62 on Friday. The firm has a market cap of $1.83 billion, a P/E ratio of -2.85 and a beta of 0.86. The business has a fifty day moving average of $4.49 and a two-hundred day moving average of $4.74. ImmunityBio has a twelve month low of $2.61 and a twelve month high of $10.53.

Institutional Trading of ImmunityBio

Institutional investors have recently made changes to their positions in the business. Captrust Financial Advisors acquired a new position in ImmunityBio during the 3rd quarter valued at about $41,000. Algert Global LLC acquired a new position in shares of ImmunityBio during the second quarter valued at about $86,000. Virtu Financial LLC purchased a new position in shares of ImmunityBio in the 3rd quarter valued at approximately $51,000. Dimensional Fund Advisors LP acquired a new stake in ImmunityBio in the 2nd quarter worth approximately $105,000. Finally, CIBC Asset Management Inc purchased a new stake in ImmunityBio during the 2nd quarter worth approximately $118,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.